ERNA — Ernexa Therapeutics Balance Sheet
0.000.00%
Annual balance sheet for Ernexa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 17 | 11.4 | 7.58 | 1.73 | 1.88 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.684 | 0.951 | 0.425 | 0.437 | 0.845 |
| Prepaid Expenses | |||||
| Total Current Assets | 18.8 | 13.7 | 9.6 | 2.35 | 3.13 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.24 | 1.32 | 33.3 | 0.755 | 0.547 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 31.5 | 22.3 | 49.1 | 5.27 | 5.83 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.68 | 7.65 | 6.57 | 2.94 | 3.11 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.02 | 10.2 | 46.9 | 3.57 | 3.43 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 25.5 | 12.1 | 2.23 | 1.7 | 2.4 |
| Total Liabilities & Shareholders' Equity | 31.5 | 22.3 | 49.1 | 5.27 | 5.83 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |